Navigation Links
Kendle to Host Conference Call and Webcast to Discuss DecisionLine Acquisition and Provide Update on Second Quarter Progress
Date:6/2/2008


CINCINNATI, June 2 /PRNewswire-FirstCall/ --

CALL DATE: Tuesday, June 3, 2008

TIME: 9:30 a.m. Eastern Time

HOST: Dr. Candace Kendle, Chairman and CEO

Kendle (Nasdaq: KNDL) will conduct a telephone conference call and simultaneous webcast on Tuesday, June 3 at 9:30 a.m. Eastern Time to discuss the acquisition of DecisionLine Clinical Research Corporation that was announced on May 30 and to provide an update on second quarter progress. A question and answer session will follow.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )

Webcast Instructions

To access the live webcast, go to http://www.kendle.com or http://www.videonewswire.com/event.asp?id=48934 . Instructions for accessing the webcast are provided at both sites. The webcast will be archived at http://www.kendle.com (click on "Investors" and then "Events & Presentations") shortly after the call for on-demand replay through 5 p.m. Eastern Time on July 3, 2008. Please note that webcast participants will not be able to ask questions.

System requirements for the webcast include Windows Media Player software and at least a 28.8 Kbps connection to the Internet. Media Player is downloadable at no charge from http://www.microsoft.com/windows/windowsmedia/default.aspx .

Conference Call Instructions

To participate in the telephone conference call, interested parties in the United States and Canada should dial (800) 399-0069. Participants outside North America should dial (706) 643-3694. A replay will be available through 5 p.m. Eastern Time on July 3 by dialing (706) 645-9291 and entering conference ID number 50042856.

About Kendle

Kendle (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services we offer experience spanning 90 countries, along with industry- leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges. Kendle was named "Top CRO to Work With" in the Thomson CenterWatch 2007 survey of U.S. investigative sites and "Best CRO" for 2007 and 2006 by leading global pharmaceutical publication Scrip World Pharmaceutical News.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202, United States or from the company's Web site at http://www.kendle.com


'/>"/>
SOURCE Kendle International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
2. Kendle Appoints Patricia Williams Vice President, Commercial Operations
3. Kendle Invites You to Attend its First Quarter 2008 Earnings Conference Call and Webcast
4. Kendle to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
5. Kendle Leaders Adopt 10b5-1 Trading Plans
6. Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference
7. Kendle Hires Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality
8. Kendle to Present at the Wachovia 2008 Healthcare Conference
9. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
10. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
11. Kendle Invites You to Attend Its Third Quarter 2007 Earnings Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Tenn. , Feb. 24, 2017 ... ("Provectus" or the "Company"), a clinical-stage oncology and ... regarding the deadline to participate in its previously ... units, consisting of shares of common stock and ... and holders of listed warrants. ...
(Date:2/24/2017)... China Cord Blood Corporation (NYSE: CO ) ... blood collection, laboratory testing, hematopoietic stem cell processing and ... results for the third quarter and first nine months ... Third Quarter of Fiscal 2017 Highlights ... increased by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)...  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company ... Opinion Leader event to highlight new clinical data that ... at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium and the ... held in-person and via live webcast on Tuesday, February ... at the Lotte New York Palace Hotel in ...
(Date:2/23/2017)... , Feb. 23, 2017 /PRNewswire/ - The Fight ... for Cancer Research (OICR) are pleased to report that ... A financing, with Johnson & Johnson Innovation – JJDC, ... include venture groups HealthCap, TPG Biotechnology Partners, and Genesys ... ...
Breaking Biology Technology:
(Date:2/9/2017)... Feb. 9, 2017 The biomass boiler market ... the biomass boiler market globally in terms of revenue ... boilers. The market for biomass boilers has been segmented ... application, and country/region. The market based on feedstock type, ... residues, biogas & energy crops, urban residues, and others. ...
(Date:2/8/2017)... Feb. 7, 2017 The biometrics market ... the confluence of organizations, desires to better authenticate ... systems (password and challenge questions), biometrics is quickly ... systems. The market is driven by use cases, ... consumer and enterprise uses cases, with consumer-facing use ...
(Date:2/7/2017)... New York , February 7, 2017 ... as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or ... management and electronic transaction processing services, is pleased to ... of the Company. Effective January 31, 2017, ... the Board of Directors, CEO and President.  An experienced ...
Breaking Biology News(10 mins):